Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection
Renovaro (NASDAQ: RENB) has announced a strategic collaboration with Nebul, a European NVIDIA NPN DGX Preferred Cloud Service Provider, to advance early disease detection. Through its subsidiary Renovaro Cube, the company plans to deploy a dedicated NVIDIA SuperPOD powered by NVIDIA DGX B200™ systems featuring the latest Blackwell GPUs.
The collaboration follows a successful pilot project confirming processing capabilities of liquid biopsy samples on NVIDIA's GPUs. Each DGX B200 system delivers up to 72 petaFLOPS of training performance and 144 petaFLOPS of inference performance. The partnership aims to develop non-invasive liquid biopsy technologies using cfDNA and 3rd-generation sequencing for faster disease detection and analysis.
Renovaro (NASDAQ: RENB) ha annunciato una collaborazione strategica con Nebul, un fornitore di servizi cloud preferito da NVIDIA NPN DGX in Europa, per avanzare nella rilevazione precoce delle malattie. Attraverso la sua controllata Renovaro Cube, l'azienda prevede di distribuire un NVIDIA SuperPOD dedicato, alimentato da sistemi NVIDIA DGX B200™ dotati delle ultime GPU Blackwell.
La collaborazione segue un progetto pilota di successo che ha confermato le capacità di elaborazione dei campioni di biopsia liquida sulle GPU di NVIDIA. Ogni sistema DGX B200 offre fino a 72 petaFLOPS di prestazioni in fase di addestramento e 144 petaFLOPS di prestazioni in fase di inferenza. L'obiettivo della partnership è sviluppare tecnologie di biopsia liquida non invasive utilizzando cfDNA e sequenziamento di terza generazione per una rilevazione e analisi più rapida delle malattie.
Renovaro (NASDAQ: RENB) ha anunciado una colaboración estratégica con Nebul, un proveedor de servicios en la nube preferido por NVIDIA NPN DGX en Europa, para avanzar en la detección temprana de enfermedades. A través de su filial Renovaro Cube, la empresa planea implementar un NVIDIA SuperPOD dedicado, impulsado por sistemas NVIDIA DGX B200™ que cuentan con las últimas GPUs Blackwell.
La colaboración sigue a un exitoso proyecto piloto que confirmó las capacidades de procesamiento de muestras de biopsia líquida en las GPUs de NVIDIA. Cada sistema DGX B200 ofrece hasta 72 petaFLOPS de rendimiento en entrenamiento y 144 petaFLOPS de rendimiento en inferencia. La asociación tiene como objetivo desarrollar tecnologías no invasivas de biopsia líquida utilizando cfDNA y secuenciación de tercera generación para una detección y análisis de enfermedades más rápidos.
Renovaro (NASDAQ: RENB)는 조기 질병 탐지를 지원하기 위해 유럽의 NVIDIA NPN DGX 선호 클라우드 서비스 제공업체인 Nebul과 전략적 협력 관계를 발표했습니다. 자회사 Renovaro Cube를 통해 이 회사는 최신 Blackwell GPU가 장착된 NVIDIA DGX B200™ 시스템으로 구동되는 전용 NVIDIA SuperPOD를 배포할 계획입니다.
이번 협력은 NVIDIA GPU에서 액체 생검 샘플의 처리 능력을 확인한 성공적인 파일럿 프로젝트에 이어 진행됩니다. 각 DGX B200 시스템은 최대 72 페타FLOPS의 훈련 성능과 144 페타FLOPS의 추론 성능을 제공합니다. 이 파트너십의 목표는 cfDNA와 3세대 시퀀싱을 이용한 비침습적 액체 생검 기술을 개발하여 질병 탐지와 분석을 보다 신속하게 하는 것입니다.
Renovaro (NASDAQ: RENB) a annoncé une collaboration stratégique avec Nebul, un fournisseur de services cloud préféré de NVIDIA NPN DGX en Europe, pour avancer dans la détection précoce des maladies. Par l'intermédiaire de sa filiale Renovaro Cube, l'entreprise prévoit de déployer un NVIDIA SuperPOD dédié alimenté par des systèmes NVIDIA DGX B200™ dotés des dernières GPU Blackwell.
Cette collaboration fait suite à un projet pilote réussi confirmant les capacités de traitement d'échantillons de biopsie liquide sur les GPU de NVIDIA. Chaque système DGX B200 offre jusqu'à 72 petaFLOPS de performance d'entraînement et 144 petaFLOPS de performance d'inférence. L'objectif de ce partenariat est de développer des technologies de biopsie liquide non invasives utilisant cfDNA et le séquençage de troisième génération pour une détection et une analyse plus rapides des maladies.
Renovaro (NASDAQ: RENB) hat eine strategische Zusammenarbeit mit Nebul, einem bevorzugten Cloud-Service-Anbieter von NVIDIA NPN DGX in Europa, angekündigt, um die frühzeitige Krankheitsdiagnose voranzutreiben. Über seine Tochtergesellschaft Renovaro Cube plant das Unternehmen, einen dedizierten NVIDIA SuperPOD einzusetzen, der mit den neuesten Blackwell-GPUs ausgestattete NVIDIA DGX B200™-Systeme betreibt.
Die Zusammenarbeit folgt auf ein erfolgreiches Pilotprojekt, das die Verarbeitungsfähigkeiten von flüssigen Biopsieproben auf den NVIDIA-GPUs bestätigt hat. Jedes DGX B200-System liefert bis zu 72 PetaFLOPS Trainingsleistung und 144 PetaFLOPS Inferenzleistung. Ziel der Partnerschaft ist die Entwicklung nicht-invasiver flüssiger Biopsietechnologien unter Verwendung von cfDNA und 3. Generation Sequenzierung für eine schnellere Krankheitsdetektion und -analyse.
- Strategic partnership with Nebul enhances computational capabilities for disease detection
- Successful completion of pilot project validating liquid biopsy processing capabilities
- Access to cutting-edge NVIDIA DGX B200 systems with superior processing power
- Technology advancement in non-invasive liquid biopsy development
- None.
Insights
The strategic collaboration between Renovaro and Nebul marks a significant technological leap in healthcare diagnostics. The deployment of NVIDIA DGX B200 systems with Blackwell GPUs represents cutting-edge AI infrastructure, with each system delivering an impressive 72 petaFLOPS for training and 144 petaFLOPS for inference - computational power that transforms the processing of genomic data from liquid biopsies. The integration of NVIDIA Parabricks functionality optimizes genomic analysis workflows, potentially reducing processing time from days to hours.
The technical architecture being implemented could revolutionize cancer detection through advanced liquid biopsy analysis. The combination of 3rd-generation sequencing technology with Blackwell GPU acceleration creates a powerful platform for processing cell-free DNA (cfDNA) at unprecedented speeds. This infrastructure investment positions Renovaro to potentially dominate the emerging market for AI-driven cancer diagnostics.
This partnership represents a pivotal advancement in liquid biopsy technology and early cancer detection. The ability to process cell-free DNA samples at accelerated speeds using next-generation AI could dramatically reduce the time from testing to diagnosis. For perspective, traditional genomic analysis can take weeks; this system could potentially deliver results in hours or days, fundamentally changing the landscape of cancer diagnostics.
The implementation of high-performance computing for analyzing cfDNA datasets could significantly improve both sensitivity and specificity in cancer detection, potentially enabling the identification of multiple cancer types from a single blood sample. This approach could revolutionize cancer screening protocols, moving away from traditional tissue biopsies toward less invasive and more comprehensive diagnostic methods.
For Renovaro, with a market cap of
The focus on cost reduction in healthcare through early detection aligns with global healthcare trends and payer priorities. Early disease detection can significantly reduce treatment costs, presenting a compelling value proposition to healthcare systems and insurance providers. This technology infrastructure investment could position Renovaro as a leading player in the multi-cancer early detection market, which is projected to reach billions in value.
Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions
LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary Renovaro Cube (the “Cube”), a leader in specific AI-driven healthcare solutions, has entered into a strategic collaboration with Nebul (www.nebul.com) a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases.
Nebul is a European NVIDIA NPN DGX Preferred Cloud Service Provider providing world-class supercomputing and GPU-accelerated business computing services, and a preferred cloud service provider in the NVIDIA Partner Network.
As part of this initiative, Renovaro Cube plans to deploy a dedicated NVIDIA SuperPOD powered by NVIDIA DGX B200™ systems, which feature the latest Blackwell GPU’s, and apply NVIDIA Parabricks functionality to ensure optimal performance on the NVIDIA clusters. Each DGX B200 system delivers up to 72 petaFLOPS of training performance and 144 petaFLOPS of inference performance, providing the computational power necessary to integrate AI across medium-sized hospitals.
The collaboration aims to harness cutting-edge AI technologies and high-performance computing (HPC) built on the latest technology available from NVIDIA to transform diagnostic and therapeutic methodologies. This important step follows on finalization of a pilot project confirming our processing capabilities of liquid biopsy samples on NVIDIA’s GPUs.
NVIDIA’s newest Blackwell GPUs are revolutionizing the speed of processing genomic data at molecular level, for example from blood (cfDNA), which is crucial for timely diagnosis and treatment selection. By leveraging their unparalleled computational efficiency, Renovaro Cube will further develop non-invasive liquid biopsy technologies using cfDNA and 3rd-generation sequencing to analyze and interpret massive cfDNA datasets at high speed, providing healthcare providers with actionable insights faster than ever before.
David Weinstein, Chief Executive Officer of Renovaro, stated, “The potential for multi-cancer early detection screening and recurrence testing will be powered by AI chips that can process vast data sets. With this material step in acquiring the latest HPC capacity, Nebul and NVIDIA will help Renovaro in driving a vision towards a future where generic diagnostic scans for diseases can be done at any point of care with a single vial of blood, helping patients detect diseases early enough to get cured. This will help to massively reduce unnecessary treatments and address the soaring costs of care that are increasingly becoming a societal problem. We expect top-tier partnerships such as these will boost our technology’s visibility and potential, laying the foundation for our go-to-market strategy.”
Nebul, recognized for its expertise in developing and managing large-scale AI infrastructure, will oversee the operation of this Superpod cluster. This collaboration extends to partnerships with institutions aiming to accelerate the adoption of AI in healthcare.
Arnold Juffer, Chief Executive Officer of Nebul, stated, “Supporting Renovaro in their mission to revolutionize healthcare through early detection and cancer diagnosis aligns well with Nebul’s mission to supply cutting-edge AI technology in healthcare. The NVIDIA partnership, combined with deep expertise, true GDPR and legal compliance is developing into a powerful force in European AI advancement. This validates Nebul’s approach into various European industries which value privacy, compliance and AI advancements. Nebul’s relentless customer intimacy and support provides a strong differentiator for partners and clients.”
Maurice van Tilburg, Renovaro's Chairman, added, "Renovaro Cube has worked on this project to utilize the compute capabilities of leading companies in this area. The partnership NVIDIA has with Nebul enhances our potential to drive true innovation in the health sector, particularly in the Netherlands and beyond."
About Nebul
Nebul offers an enterprise class European private AI cloud combined with the convenience, scale, and reach of big global hyper scalers into a genuine European Sovereign-Hybrid Cloud. Using the full range of NVIDIA technologies, new capabilities like Private AI, Digital Twins and Omniverse can be enabled more easily and quickly without sharing sensitive corporate data with third parties you do not control. Nebul Cloud enables AI development and operations using the latest technologies. From Generative AI to Digital Twins and Omniverse simulations, Nebul empowers European organizations to harness the power of AI securely and efficiently. Nebul has achieved NEN 7510 and ISO 27001 certifications, demonstrating compliance with stringent standards for securely processing European healthcare patient data, ensuring data confidentiality, integrity, and availability for AI applications. Nebul on the web: nebul.com
About Renovaro Cube
Renovaro Cube is a pioneer in AI-based molecular diagnostics, committed to revolutionizing healthcare through advanced data analysis. Its platform integrates cutting-edge AI capabilities with state-of-the-art HPC infrastructure to provide unparalleled insights into multi-omic data for early detection of diseases based on non-invasive testing using liquid biopsy (blood).
Renovaro Cube’s AI platform is purpose-built to process and analyze multi-omic molecular data, facilitating the discovery of biomarkers critical for early cancer detection, monitoring, and treatment personalization. Originally awarded for its fintech application, this platform has been reengineered for healthcare, offering:
- Sequence Processing: Transform raw molecular data from patient samples into clean, analyzable formats using advanced sequencing and alignment technologies, ensuring the highest quality for downstream analysis.
- Biomarker Discovery: Harness unique algorithms and multi-omic pipelines to identify biologically relevant cancer biomarkers, providing critical insights into disease mechanisms and potential therapeutic targets.
- AI Factory: Employ sophisticated machine learning models to predict cancer presence, origin, and stage based on extracted biomarker features. These models are trained on vast datasets to enhance accuracy and reliability, supporting early detection and personalized treatment strategies.
- Precision Diagnostics: Offer an interactive interface for visualizing data, generating comprehensive clinical reports, and delivering actionable insights across various omic layers and biomarkers. This interface empowers healthcare professionals to make informed decisions with confidence.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and Renovaro Cube.
Renovaro Cube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. Renovaro Cube intervenes at a stage where potential therapy can be most effective. Renovaro Cube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
karen@Renovaro Cube.com and STarsh@Renovarogroup.com
FAQ
What is the purpose of Renovaro's (RENB) collaboration with Nebul?
What computational power will RENB's new NVIDIA DGX B200 systems provide?
How will RENB's partnership with Nebul improve disease detection?
What technology breakthrough has RENB achieved in liquid biopsy testing?
How will RENB's new AI infrastructure impact healthcare delivery?
